Wyeth wins expanded indication for Tygacil

Wyeth says it has won FDA approval for an expanded indication for pneumonia med Tygacil (tigecycline). The med will now be available for the treatment of adults with community-acquired bacterial pneumonia (CABP). The decision was based on the results of two randomized, double-blind conducted in 28 different countries and including 859 patients with CABP.

Tygacil was initially approved in 2005 for the treatment of complicated intra-abdominal infections (cIAI) and complicated skin and skin structure infections (cSSSI).

"The approval of this new indication is timely. Antibiotic resistance continues to grow and new antimicrobials are needed," says Joseph Camardo, M.D., Senior Vice President, Global Medical Affairs, Wyeth Pharmaceuticals. "The approval of TYGACIL for CABP is an important milestone in Wyeth's commitment to exploring new treatment options in the anti-infective therapeutic area."

- read the Wyeth release

Launch Readiness

Optimize cross-functional collaboration and engage with key stakeholders for the successful launch of a product

Join the Launch Readiness for Medical Affairs & Communications Teams Summit to learn best practices in taking a structured approach to enhance medical affairs activities surrounding a launch and increase knowledge and communication with thought leaders.